Notable Labs Reports 2023 Financial Results and Provides a Business Update
April 12, 2024 08:00 ET
|
Notable Labs
FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies...
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
April 09, 2024 17:15 ET
|
Notable Labs
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid...
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
April 08, 2024 12:00 ET
|
Notable Labs
FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer...
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
March 05, 2024 16:35 ET
|
Notable Labs
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer...
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
February 22, 2024 08:00 ET
|
Notable Labs
Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk, time, and cost of drug developmentVolasertib Phase 2 trial initiation...
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome
December 18, 2023 08:00 ET
|
Notable Labs; CicloMed, LLC
- PPMP Accurately Predicted Patient Outcomes in Fosciclopirox Phase 2a Leukemia Trial - - Predictive Results Further Advance PPMP and Corroborate Outcomes from 4 PPMP Validation Trials - - Furthers...
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit
December 04, 2023 16:30 ET
|
Notable Labs
FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for...
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023
November 14, 2023 16:15 ET
|
Notable Labs
-Summarizes third quarter 2023 financials of pre-Merger VBLT as of September 30th- -Third quarter financial information of Notable Labs, Inc. and pro forma combined financial information of Notable...
Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML
November 09, 2023 16:05 ET
|
Notable Labs
– Article Published in November 9th Issue of ASCO’s Journal of Clinical Oncology Precision Oncology (JCO PO) – – Results highlight PPMP as a tool for identifying most promising drug combinations for...
Notable Labs Closes Merger Transaction With VBL Therapeutics
October 16, 2023 13:01 ET
|
Notable Labs
- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned...